H2 Receptor Antagonist Market: Key Growth Challenges & Future Outlook
- Rep Id : XPLREP3989
- Published On : July, 2019
- No. of Pages : 204
- Category : Healthcare
The rising prevalence of gastroesophageal reflux disease (GERD) is different geographically. In eastern countries the prevalence of GERD is lower as compared to western countries where the prevalence of GERD is higher. The accurate data of target population with any GERD symptoms is hard to track, as most of the symptoms are often ignored and treated as regular gastric difficulties.
The H2-receptor antagonists market report offers a detailed analysis on the revenue opportunities and trends present in the H2-receptor antagonists market. The detailed analysis, along with insights on drug innovation, timeline, and pricing for each drug candidate is included in this report. The present macroeconomic factors influencing the dynamics of the H2-receptor antagonists market are also briefly explained.
Prevalence of GERD Creating Diverse growth prospects for manufacturers of H2-receptor antagonists
H2-receptor antagonists are a traditional form of medication used for GERD cases, and manufacturers in the business should target geographies where the prevalence of GERD is known to be high, which include the U.S., Norway, Sweden, Brazil, and others.
Major government healthcare bodies take an account of people diagnosed or subject to GERD indications, and this data helps estimate the consumer potential for manufacturers to invest in each region. The growing prevalence in terms of GERD is a major driving factor for the H2-receptor antagonists market in terms of potential consumers with purchasing power. However, an equally important indication of H2-receptor antagonists is a peptic ulcer, which is reportedly decreasing on a global level.
Many indirect factors are contributing to growth in the incidence of GERD, which include the choice of food, physical habits, and prolonged health problems. These are among the main factors contributing to the growth in the patient pool, which is directly contributing to the growth of the H2-receptor antagonists market.
Hence, manufacturers need to implement business strategies to promote the use of H2-receptor antagonist drugs. The adoption of H2 receptor antagonists is low as compared to PPI, however, with the right clinical adjustments, the market for H2 receptor antagonists is likely to witness significant growth due to the increasing incidence of GERD.
A Shift from ‘Prescription’ to ‘OTC’ Drugs
The planned introduction of various Over-the-Counter (OTC) drugs has renewed interest among many consumers. Expenditure on prescription drugs is increasing faster than any other medical service sector, and over the years, spending on prescription drugs is growing in double digits. The rising cost is attracting the attention of key leaders in the healthcare industry, politics, and consumer health groups.
The current expansion for OTC drugs is explainable, and factors such as cost containment efforts from healthcare organizations, the deregulation of prescription drugs, and a steady increase in the number of generic products due to patent expiration are contributing to the growth of the market.
The entire paradigm for H2 receptor antagonists has also changed over time due to the increasing popularity of the concept of self-care. Hence, consumers are embracing OTC H2 receptor antagonists as they do not require them to pay service charges to healthcare bodies that provide a treatment plan.
The spending for OTC H2 receptor antagonists is minimal as compared to prescription-based drugs. H2 receptor antagonists are mostly available in the generic form, and the concentration of the active ingredient present is responsible for the availability of the drug either in a prescription or OTC form.
Healthcare regulation bodies provide excess benefits to manufacturers leading to the transition from prescription to OTC H2 receptor antagonists. The drug price competition and Patent Restoration Act of 1984 provides a patent extension of 3 years, only if the manufacturer switches the prescription drug to a more suited OTC type.
In April 1995, famotidine (Pepcid AC) became the first of the H2 receptor antagonists to be switched to an OTC status. Other drug types present in the drug class switched to OTC respectively, the manufacturers implemented a critical business strategy by keeping the prescription drug available in the market and launching OTC drugs with low doses.
H2-Receptor Antagonists Market: Competitive Landscape
The H2-receptor antagonists market includes some of the key manufacturers of H2-receptor antagonists based on their market dynamics and financial standing. The H2-receptor antagonists market mostly comprises generic manufacturers, and there are many small-scale manufacturers present in this mature market.
Some of the manufacturers profiled in the H2-receptor antagonists market report include
- Alembic Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Helios Pharmaceuticals
- Intas Pharmaceuticals Ltd.
- Mankind Pharma Ltd.
- Torrent Pharmaceuticals Ltd.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline Plc.
A recent market study published by XploreMR - “H2 Receptor Antagonist Market: Global Industry Analysis 2014-2018 & Forecast, 2019-2029” consists of a complete research on the most important market dynamics influencing the same. A thorough research on the factors levelling the current growth parameters of the H2 receptor antagonist market is explained, the present growth prospects for the market are obtained with maximum precision.
The H2 receptor antagonist market report features the unique and salient factors that are likely to significantly impact the development of the H2 receptor antagonist market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the H2 receptor antagonist market in the upcoming years. The report provides detailed information about the current and future growth prospects of the H2 receptor antagonist market in the most comprehensive manner for the better understanding of readers.
Chapter 1 – Executive Summary
The H2 receptor antagonist market report commences with an executive summary of the key findings and key statistics of the H2 receptor antagonist market. It also includes the market value (US$ million) estimates of the leading segments of the H2 receptor antagonist market.
Chapter 2 – Market Overview
Readers can find detailed market structure including all the inclusions and exclusion, which helps the reader understand the scope of the H2 receptor antagonist market report. This section also includes prominent definition for H2 receptor antagonist market, which helps understand the basic information about the H2 receptor antagonist. This section also highlights the inclusions and exclusions,
Chapter 3 – Key Market Trends
This section explains about the key trends followed by the manufacturer and consumer in H2 receptor antagonist market. This section provides list of key major mergers and acquisitions which helps in building a comprehensive understanding. Major product offerings form each manufacture is also marked in this chapter. Competition of Zantac v. Tagamet is also briefly explained. It helps reader to understand trends impacting the growth of H2 receptor antagonist market.
Chapter 4 – Key Success Factors
This chapter highlights the key success factors of the H2 receptor antagonist market report, which include disease epidemiology, key regulations, clinical trials, five forces analysis and a competitive assessment for drug types. Readers can find the detailed requirements and scenarios present in the H2 receptor antagonist market.
Chapter 5 – Global H2 Receptor Antagonist Market: Pricing Analysis
This section highlights the average price of H2 receptor antagonist in different region throughout the globe. The pricing benchmark for manufacturer level pricing and distributor level pricing is analysed in this section.
Chapter 6 – Global H2 Receptor Antagonist Market Value Analysis 2014-2018 & Forecast, 2019-2029
This section explains the global market analysis and forecast for the H2 receptor antagonist market. It also highlights the incremental opportunity for the H2 receptor antagonist market along with the absolute dollar opportunity for every year between the forecast period of 2019-2029.
Chapter 7 – Market Background
This chapter explains the key macro-economic factors that are expected to influence the growth of the H2 receptor antagonist market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the H2 receptor antagonist market. This chapter also highlights the key dynamics of the H2 receptor antagonist market, which include the drivers and restraints.
Chapter 8 – Global H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029, By Drug Type
Based on drug type, the H2 receptor antagonist market is segmented as Cimetidine, Ranitidine, Famotidine and Nizatidine.
Chapter 9 – Global H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029, By Indication
Based on Indication, the H2 receptor antagonist market is segmented as Gastric Acidity, Peptic Ulcers and gastroesophageal reflux disease. This section helps readers understand the penetration of H2 receptor antagonist market over the forecast period.
Chapter 10 – Global H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029, By Dosage Form
Based on dosage form, the H2 receptor antagonist market is segmented as tablet, solution for injection, suspension, capsule and syrup. In this chapter, readers can understand the global market attractive analysis based on dosage form
Chapter 11 – Global H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029, By Distribution Channel
Based on distribution channel, the H2 receptor antagonist market is segmented as hospital pharmacies, retail pharmacies, online pharmacies and drug stores. In this chapter, readers can understand the global market attractive analysis based on distribution channel segment.
Chapter 12 – Global H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029, By Region
This chapter explains how the H2 receptor antagonist market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East & Africa (MEA).
Chapter 13 – North America H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
This chapter includes a detailed analysis of the growth of the North America H2 receptor antagonist market along with a country-wise assessment, which includes the U.S. and Canada. Readers can also find the key takeaways of this region, and market growth based on drug type, indication, dosage form, distribution channel and country for North America H2 receptor antagonist market
Chapter 14 – Latin America H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
This chapter contains a snapshot of the Latin America H2 receptor antagonist market. It includes the growth prospects of the H2 receptor antagonist market in the leading LATAM countries such as Brazil, Mexico and the rest of Latin America region.
Chapter 15 –Europe H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
This section contains important growth prospects of the H2 receptor antagonist market based on drug type, indication, dosage form, distribution channel in several European countries, such as the U.K., Germany, France, Italy, Spain, Benelux, Russia and the rest of Europe.
Chapter 16 –East Asia H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
This chapter highlights the growth of the H2 receptor antagonist market focusing on China, Japan and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the H2 Receptor Antagonist market in East Asia.
Chapter 17 – South Asia H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
India, Indonesia, Thailand, Malaysia are the leading countries in the South Asia region that are taken as the prime subjects of assessment to obtain the growth prospects of the South Asia H2 receptor antagonist market. Readers can find detailed information about the growth parameters of the South Asia H2 Receptor Antagonist market during the period 2019-2029.
Chapter 18 – Oceania H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
Readers can find important factors that can significantly impact the growth of the H2 receptor antagonist market in Australia and New Zealand during the forecast period based on the market segmentation.
Chapter 19 – MEA H2 Receptor Antagonist Market Analysis 2014-2018 & Forecast, 2019-2029
This chapter provides information about the growth of the H2 receptor antagonist market in the major countries of the MEA region, such as GCC Countries and South Africa, during the period 2019-2029.
Chapter 20 – Competition Landscape
In this chapter, readers can find a comprehensive list of all the leading manufacturers in the H2 receptor antagonist market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the players featured in the H2 receptor antagonist market report, are Abbott, Alembic Pharmaceuticals Ltd, Cadila Healthcare Ltd, Caple, Cipla Ltd., Dr Reddy'S Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Helios Pharmaceuticals, Intas Pharmaceuticals Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline Plc.
Chapter 21 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the H2 receptor antagonist market report.
Chapter 22 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions and important qualitative information & quantitative information about the H2 receptor antagonist market.